Introducing a New Concept for Value-Driven Acceleration in Biopharma Development

Publication
Article
BioPharm InternationalBioPharm International, October 2022
Volume 35
Issue 10
Pages: 34–41

Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Ipopba/Stock.adobe.com – Using a minimum valuable product and process approach would make it is possible to discipline and structure the development of biopharmaceuticals in the fastest way possible.

Ipopba/Stock.adobe.com

This opinion paper seeks to introduce a disruptive model to accelerate product and process development in the biopharmaceutical industry, especially for vaccines. This model is based on the minimum valuable product and process (MVaP&P), a new concept that allows for adaptation and acceleration, which would enable agility in the way biopharmaceuticals are developed. This article discusses how the MVaP&P approach would make it is possible to discipline and structure biopharmaceutical development to achieve a phase-appropriate and strategy-aligned product in the fastest time possible.

Click here for a PDF of this article.

Peer-reviewed research

Submitted: May 12, 2022
Article accepted: June 28, 2022

About the authors

Matthew Sanders* is vice-president, head of Global Drug Substance; Roland Mainil is director, Technical Development Lead; and Wael Chahim* is associate director, Development Unit Head; all at GSK, Rixensart, Belgium.

*Both authors contributed equally to this paper.

Article details

BioPharm International
Vol. 35, No. 10
October 2022
Pages: 34–41

Citation

When referring to this article, please cite it as M. Sanders, R. Mainil, and W. Chahim, “Introducing a New Concept for Value-Driven Acceleration in Biopharma Development,” BioPharm International 35 (10) 34–41 (2022).

Recent Videos
Adam Sherlock, CEO of Qinecsa Solutions
Eswar Iyer, Aikium Inc.
Leroy (Lee) Hood, MD, PhD
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
Buy, Sell, Hold: Cell and Gene Therapy
© 2025 MJH Life Sciences

All rights reserved.